Home
Clinical Trials
A Study Comparing Efficacy, S...

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

NCT ID: NCT04320342

Last Updated: 2025-04-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

3433 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-28

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

NCT03590379

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

NCT05097014

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE4

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

NCT00476099

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT03197818

COPD (Chronic Obstructive Pulmonary Disease)

COMPLETED PHASE3

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

NCT01049360

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase III, multinational, multicenter, randomized, double-blind active controlled 2-arm parallel group study to compare efficacy, safety, and tolerability of CHF 5993 pMDI with CHF 1535 pMDI with respect to lung function, incidence of moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes.

After screening, eligible subjects will enter 2-week run-in period using their regular COPD maintenance therapies after which they will be randomized to one of 2 study treatment groups. Following randomization, subjects will be assessed after 4 weeks then at 6-week intervals thereafter for a period of 52 weeks. A follow-up safety phone call will be performed a week after the last clinic visit. A subset of subjects consenting to participate in the pharmacokinetic substudy will undergo additional assessments (totaling 3 visits) during the scheduled study visits.

During the study, daily symptoms, rescue medication use and compliance with the study drug will be recorded via a subject electronic diary. Subject concomitant medications, adverse events, and healthcare resource utilization will be assessed and recorded throughout the study. At intermittent study visits, subjects will undergo vital signs examinations including weight, spirometry measurements, and 12-lead ECG. Symptoms and COPD health status will be assessed through disease specific questionnaires. Routine hematology, blood chemistry, and serum pregnancy testing will be performed before enrollment and at end of study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD COPD Exacerbation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BDP/FF/GB - CHF 5993

Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler

Group Type EXPERIMENTAL

Beclomethasone Dipropionate

Intervention Type DRUG

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Glycopyrronium Bromide

Intervention Type DRUG

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg

Formoterol Fumarate

Intervention Type DRUG

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

BDP/FF - CHF 1535

Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler

Group Type ACTIVE_COMPARATOR

Beclomethasone Dipropionate

Intervention Type DRUG

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Formoterol Fumarate

Intervention Type DRUG

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beclomethasone Dipropionate

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Intervention Type DRUG

Glycopyrronium Bromide

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg

Intervention Type DRUG

Formoterol Fumarate

Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BDP glycopyrrolate GB FF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated written informed consent must be obtained prior to initiating any study-related procedures
* Outpatient
* Male or female subjects aged ≥40 years
* Female subjects:

1. WOCBP fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).
2. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile as per definitions given in Appendix 5). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges)
* COPD diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report
* Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years \[pack-years = (number of cigarettes per day x number of years)/20\]
* COPD Assessment Test (CAT) score ≥10
* A pre- and post-bronchodilator FEV1/FVC ratio \<0.70 at screening
* A post-bronchodilator FEV1 \<50% predicted normal at screening and a documented history of ≥1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator FEV1 ≥50% and \<80% of predicted normal at screening and a documented history of ≥2 moderate COPD exacerbations or ≥1 severe COPD exacerbation in the previous 12 months
* Subjects receiving daily inhaled maintenance therapy for their COPD, at a stable dose for at least 3 months prior to the screening and randomization visits
* Documentation (including imagery and report) of chest x-ray (CXR) or CT scan performed within 6 months prior to the screening visit, without evidence of significant abnormalities (other than those related to the presence of COPD).
* A cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary.

Exclusion Criteria

* Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating
* Subjects using the following medications prior to the screening visit and during the run-in period:

1. Systemic/oral/parenteral corticosteroids in the prior 4 weeks
2. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) or COPD exacerbation in the prior 4 weeks
3. Any long-term chronic maintenance use of antibiotic treatment in the prior 4 weeks
4. Oral xanthine derivatives (e.g. theophylline) in the prior 7 days
* A moderate or severe COPD exacerbation or a respiratory tract infection (e.g., pneumonia) that has not resolved ≤14 days prior to the screening visit or during the run-in period
* Current treatment with non-cardioselective β-blockers
* Requirement of long term (\> 15 hours daily) oxygen therapy
* Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to investigator's judgement.
* Lung transplant surgery or lung volume reduction surgery (subjects with lung volume reduction surgery are excluded if the procedure was performed within 1 year before the Screening visit)
* Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator, would prevent use of anticholinergic agents
* History of hypersensitivity to M3 receptor antagonists, β2 agonists, corticosteroids or any of the excipients contained in any of the study drugs used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement
* Subject has severe, acute or uncontrolled cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class IV, left ventricular failure, acute myocardial infarction or unstable angina) in the last 6 months
* An abnormal and clinically significant 12-lead ECG at either the screening or randomization visit. This is characterized as but not limited to any of the following findings:

1. Atrial fibrillation (AF) with rapid ventricular response \> 120 bpm
2. Ventricular tachycardias (sustained, non-sustained \[\>3 up to 30 sec\])
3. Evidence of Mobitz Type II second degree or third-degree atrioventricular block
4. Prolonged QTcF (\>450ms for males, or \>470ms for females). This criterion is not applicable for subjects with a pacemaker or permanent AF.
* Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
* Unstable or uncontrolled concurrent disease which may impact the efficacy or safety of the study drug or the subject's participation in the study according to investigator's judgment
* Malignancy that has not been in complete remission for at least 1 year or any untreated localized carcinomas
* History of alcohol abuse and/or substance/drug abuse within 12 months prior to the screening visit
* Receipt of any other investigational drug within 1 month or 5 half-lives (whichever is greater) prior to the screening visit or have been previously randomized in this trial, or are currently participating in another clinical trial
* Currently in the acute phase of a pulmonary rehabilitation program within 4 weeks before the screening visit or planning to enroll in the acute phase of such a program during the study. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
* Mentally or legally incapacitated, or subjects incarcerated as a result of an official or judicial order
* Major surgery in the 3 months prior to the screening visit or have a planned surgery during the trial
* Non-satisfactory compliance with the eDiary (\<65% or \>135%) during the run-in period
* Subjects requiring the use of spacer device or nebulizer for administration of maintenance COPD therapies.
* Veins unsuitable for repeat venipuncture
* Blood donation or blood loss (≥450mL) in the 4 weeks before randomization

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gregory M Feldman, MD

Role: PRINCIPAL_INVESTIGATOR

Vitalink Research - Spartanburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chiesi Clinical Trial Site 840350

Birmingham, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840186

Dothan, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840258

Foley, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840279

Jasper, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840433

Mobile, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840206

Montgomery, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840249

Muscle Shoals, Alabama, United States

Site Status

Chiesi Clinical Trial Site 840406

Chandler, Arizona, United States

Site Status

Chiesi Clinical Trial Site 840402

Peoria, Arizona, United States

Site Status

Chiesi Clinical Trial Site 840349

Tucson, Arizona, United States

Site Status

Chiesi Clinical Trial Site 840404

Covina, California, United States

Site Status

Chiesi Clinical Trial Site 840209

Escondido, California, United States

Site Status

Chiesi Clinical Trial Site 840427

La Palma, California, United States

Site Status

Chiesi Clinical Trial Site 840358

Lomita, California, United States

Site Status

Chiesi Clinical Trial Site 840173

Newport Beach, California, United States

Site Status

Chiesi Clinical Trial Site 840208

Northridge, California, United States

Site Status

Chiesi Clinical Trial Site 840277

Northridge, California, United States

Site Status

Chiesi Clinical Trial Site 840364

Redding, California, United States

Site Status

Chiesi Clinical Trial Site 840226

Sacramento, California, United States

Site Status

Chiesi Clinical Trial Site 840405

Sacramento, California, United States

Site Status

Chiesi Clinical Trial Site 840107

San Diego, California, United States

Site Status

Chiesi Clinical Trial Site 840373

Santa Ana, California, United States

Site Status

Chiesi Clinical Trial Site 840164

Upland, California, United States

Site Status

Chiesi Clinical Trial Site 840174

West Covina, California, United States

Site Status

Chiesi Clinical Trial Site 840144

Westminster, California, United States

Site Status

Chiesi Clinical Trial Site 840441

Aurora, Colorado, United States

Site Status

Chiesi Clinical Trial Site 840229

Boulder, Colorado, United States

Site Status

Chiesi Clinical Trial Site 840399

Norwalk, Connecticut, United States

Site Status

Chiesi Clinical Trial Site 840116

Altamonte Springs, Florida, United States

Site Status

Chiesi Clinical Trial Site 840268

Aventura, Florida, United States

Site Status

Chiesi Clinical Trial Site 840192

Brandon, Florida, United States

Site Status

Chiesi Clinical Trial Site 840310

Brooksville, Florida, United States

Site Status

Chiesi Clinical Trial Site 840240

Chiefland, Florida, United States

Site Status

Chiesi Clinical Trial Site 840153

Clearwater, Florida, United States

Site Status

Chiesi Clinical Trial Site 840272

Coral Gables, Florida, United States

Site Status

Chiesi Clinical Trial Site 840304

Coral Gables, Florida, United States

Site Status

Chiesi Clinical Trial Site 840193

Cutler Bay, Florida, United States

Site Status

Chiesi Clinical Trial Site 840311

Cutler Bay, Florida, United States

Site Status

Chiesi Clinical Trial Site 840335

Cutler Bay, Florida, United States

Site Status

Chiesi Clinical Trial Site 840141

Daytona Beach, Florida, United States

Site Status

Chiesi Clinical Trial Site 840133

DeLand, Florida, United States

Site Status